Thromb Haemost 1984; 51(02): 269-271
DOI: 10.1055/s-0038-1661074
Original Article
Schattauer GmbH Stuttgart

Effects of Acetylsalicylic Acid on Human Platelet Function In Vivo at Salicylate Steady State

R Simrock
The Department of Internal Medicine, Division of Angiology, J. W. Goethe University, Frankfurt/M., F.R.G.
,
A Missalla
The Department of Internal Medicine, Division of Angiology, J. W. Goethe University, Frankfurt/M., F.R.G.
,
P Schwidtal
The Department of Internal Medicine, Division of Angiology, J. W. Goethe University, Frankfurt/M., F.R.G.
,
V Lischke
The Department of Internal Medicine, Division of Angiology, J. W. Goethe University, Frankfurt/M., F.R.G.
,
H K Breddin
The Department of Internal Medicine, Division of Angiology, J. W. Goethe University, Frankfurt/M., F.R.G.
› Author Affiliations
Further Information

Publication History

Received 07 October 1983

Accepted 27 February 1984

Publication Date:
19 July 2018 (online)

Summary

The results of clinical trials concerning the use of acetylsalicylic acid (ASA) as antithrombotic drug are contradictory. Inhibition by ASA of platelet prostaglandin synthesis and aggregation is prevented by its metabolite salicylic acid (SA) in animals and in human platelets in vitro. It was suggested that ASA might produce its own inhibitor, thereby diminishing its efficiency in thromboembolic disease.

In four healthy male subjects there was no difference in inhibition of collagen-induced platelet aggregation after the administration of 500 mg ASA alone or at salicylate steady state (3 g SA daily). But the inhibition of tissue-extract-induced platelet shape change was diminished and shortened by pretreatment with SA. We conclude that SA does not inhibit the effects of ASA on human platelet aggregation in vivo in therapeutic dose ranges. The clinical importance of the SA/ASA-interaction on tissue-extract-induced platelet shape change remains to be clarified.

 
  • References

  • 1 Weiss HJ, Aledort LM. Impaired platelet/connective tissue reaction in man after aspirin ingestion. Lancet 1967; 2: 495-497
  • 2 Zucker MB, Peterson J. Inhibition of adenosine diphosphate-induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion. Proc Soc Exp Biol Med 1968; 127: 547-551
  • 3 O’Brien JR. Effects of salicylates on human platelets. Lancet 1968; 1: 779-783
  • 4 Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Nat Acad Sci USA 1975; 72: 3073-3076
  • 5 Pietsch U, Lippmann M, Scharrer J, Breddin K. Neue Befunde zur Wirkung der Acetylsalicylsaure: Die Hemmwirkung auf den Formen- wandel der Thrombozyten und ihre Bedeutung fur die Dosierung als Antithrombotikum. In Alexander K, Cachovan M. (Ed.) Diabetische Angiopathien. 1977. pp 348-352
  • 6 Bamberg E, Bauer O, Herrmann W, Kroemer H, Lippmann M, Müller Ch, Stagmann H, Breddin K. Primarer Formwandel der Thrombozyten in vitro. Blut 1978; 37: 327-339
  • 7 Breddin K. Zum Wirkungsmechanismus und zur Dosierung thrombozytenfunktionshemmender Medikamente. In Prophylaxe venoser, peripherer, kardialer und zerebraler GefaBkrankheiten mit Acetylsalicylsaure. Stuttgart - New York: 1981. pp 9-22
  • 8 Breddin K. Experimental and clinical investigations on the adhesion and aggregation of human platelets. Exp Biol Med 1968; 14: 23
  • 9 Rowland M, Riegelman S, Harris PA, Sholkoff SD. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci 1972; 61: 379-385
  • 10 Levy G. Pharmacokinetics of salicylate elimination in man. J Pharm Sci 1965; 54: 959-967
  • 11 Simrock R, Spahn H, Breddin K, Mutschler E. Reversible Hemmung der Thrombozytenstimulation durch Acetylsalicylsäure und ihre Bedeutung für die antithrombotische Therapie. Klin Wochenschr 1983; 61: 297-302
  • 12 Weiss HJ, Aledort LM, Kochwa S. The effects of salicylates on the hemostatic properties of platelets in man. J Clin Invest 1968; 47: 2169-2180
  • 13 Vargaftig BB. Platelets and inflammation. Agents Actions 1977; Suppl 3: 75-92
  • 14 Vargaftig BB. The inhibition of cyclooxygenase of rabbit platelets by aspirin is prevented by salicylic acid and by phenanthrolines. Eur J Pharmacol 1978; 50: 231-241
  • 15 Vargaftig BB. Salicylic acid fails to inhibit generation of thromboxane A2 activity in platelets after in vivo administration to the rat. J Pharm Pharmacol 1978; 30: 101-104
  • 16 Vargaftig BB, Lefort J. Acute hypotension due to carrageenan, arachidonic acid and slow reacting substance C in the rabbit: role of platelets and nature of pharmacological antagonism. Eur J Pharmacol 1977; 43: 125-141
  • 17 Sherwood J, Kreutner W. Salicylic acid prevents the inhibition of platelet prostaglandin synthetase by indomethacin-like antiinflammatory agents. Fed Proc 1978; 37: 605
  • 18 Merino J, Livio M, Rajtar G, DeGaetano G. Salicylate reverses in vitro aspirin inhibition of rat platelet and vascular prostaglandin generation. Biochem Pharmacol 1980; 39: 1093-1096
  • 19 Cerletti C, Livio M, DeGaetano G. Non-steroidal antiinflammatory drugs react with two sites on platelet cyclooxygenase. Biochim Biophys Acta 1981; 714: 122-128
  • 20 DeCastellamau C, Cerletti C, Dejana E, Galletti F, Latini R, Livio M, DeGaetano G. Salicylate-aspirin interaction and thrombosis prevention trials. Thromb Haemostas 1981; 45: 294
  • 21 Dejana E, Cerletti C, DeCastellamau C, Livio M, Galetti F, Latini R, DeGaetano G. Salicylate-aspirin interaction in the rat. J Clin Invest 1981; 68: 1108-1112
  • 22 Ali M, McDonald JW. Interference by sulfinpyrazone and salicylate of aspirin inhibition of platelet cyclooxygenase activity. Prostaglandins Med 1979; 3: 327-332
  • 23 Brandtmark B, Hedner U, Melander A, Wåhlin-Boll E. Salicylate inhibition of antiplatelet effect of aspirin. Lancet 1981; 1: 1349
  • 24 Simrock R, Lischke V, Missalla A, Schwidtal P, Breddin HK. Die Acetylsalicylsaurewirkung auf Partialfunktionen menschlicher Thrombozyten wird in vivo durch Salicylsaure nicht gehemmt. Klin Wochenschr 1983; 62: 225-230
  • 25 Levy G, Tsuchiya T. Salicylate accumulation kinetics in man. New Engl J Med 1972; 287: 430-432
  • 26 Kirchmaier C, Bender N, Wilhelm B, Al Sayegh A, Breddin K. A hemostasis activating factor (HAF) in subcutaneous tissue extracts: effects on morphological platelet changes. Thromb Res 1979; 16: 81-91
  • 27 Bender N, Kirchmaier C, Bartsch B, Lindenborn D, Breddin K. Stimulation of blood platelets by extracts of sucutaneous tissue. Thromb Res 1979; 14: 341-351
  • 28 Lord E. The use of the range in place of the standard deviation in the t-test. Biometrika 1947; 34: 41-67
  • 29 Hanley SP, Hughes J. Failure of salicylate to reduce inhibition of human venous prostacyclin in synthesis by conventional dose aspirin. Thromb Haemostas 1983; 49: 51-52
  • 30 Philp RB, Paul ML. Non-interference by salicylate with aspirin inhibition of arterial thrombosis in rats. Prostaglandins Med 1981; 7: 91-94
  • 31 Philp RB, Paul ML, Killackey JJ, Killackey BA. The influence of dose, time of administration, body temperature and salicylate kinetics on the antithrombotic action of acetylsalicylic acid in male rats. Haemostasis 1983; 13: 42-52
  • 32 Rosenberg FJ, Gimber-Phillips PE, Groblewski GE, Davison C, Phillips DK, Goralnik SJ, Cahill ED. Acetylsalicylic acid: inhibition of platelet aggregation in the rabbit. J Pharmacol Exp Ther 1971; 179: 410-418